Primary hyperhidrosis: an updated review.

Introduction

Hyperhidrosis (HH) is often defined as primary HH (PHH), also known as idiopathic or essential HH, where the cause of the excessive sweating beyond thermoregulation needs is unknown, and secondary HH (SHH), where the cause is due to an underlying medical condition, medication or other systemic affect. HH can further be classified as focal, where it affects a localized area of the body, or generalized, where it affects a large area or the entire body. PHH tends to be more focal, whilst SHH is often more generalized. 1 , 2 This narrative review aims to provide an overview of HH with the context of highlighting key pharmacological treatments to guide management.

Methods

A search was conducted in February 2025 in Ovid Medline, EMBASE and Cochrane Central Register of Controlled Trials (CENTRAL) using the key term “hyperhidrosis”. The search strategy included all observational studies (including case reports and case series), clinical trials (including open trials, non-randomized controlled trials and randomized controlled trials) and reviews (including narrative reviews, clinical guidelines and meta-analyses) published within the past 10 years. ClinicalKey, DynaMed, Wikipedia and Google were also searched to enrich the review. Additional articles were culled by searching the reference lists. Only papers published in the English literature were included in this review. The information retrieved from the search was used in the compilation of the present article.

Review

Epidemiology

The estimated worldwide prevalence of PHH has been reported to be between 0.072% and 9%. 3 – 14 HH (both primary and secondary) prevalence in the USA has been estimated at 2.8–4.8% of the population, whereas prevalence in Germany has been estimated at 16.3%. 5 , 13 PHH is the most common form, representing 93% of all patients with HH. 15 , 16 Although reported sex differences in PHH prevalence vary across studies — potentially due to differing subtype classifications and healthcare-seeking behaviours — the overall consensus is that, overall, PHH affects both sexes equally. 15 – 17 Additionally, the prevalence of PHH may be independent of geographical location, however, there may be differences in specific subtypes of PHH depending on sex, ethnicity and age. 17 Further, 30–65% of patients with PHH describe having a positive family history indicating a strong genetic link to the condition. 18

Aetiopathogenesis

In PHH, patients produce excessive sweating that exceeds the physiological needs for thermoregulation, resulting in a decreased quality of life and burden on patients. 19 The excessive response of PHH is inappropriate and does not match the typical response one would expect based on an emotional or physiological stimulus. The proposed major causes include autonomic nervous system effects, genetics and environmental factors. 19

There are two main types of sweat glands, eccrine sweat glands and apocrine sweat glands. 19 Whilst eccrine sweat glands are found across the entire body and produce sweat for thermoregulation, apocrine sweat glands are primarily found in hair follicles and contribute towards body odour. 19 Eccrine sweat glands are more common (75% of all sweat glands) and are produced during the embryonic stage of life with none produced after birth. The distribution of these sweat glands parallels the common areas affected in PHH with the highest density of sweat glands in the palmoplantar and axillae regions. 19 Eccrine sweat glands are the culprit in PHH and are innervated by cholinergic fibres of the sympathetic nervous system (SNS) to produce odourless and colourless sweat that consists of mainly water, electrolytes (sodium and chloride), urea and nitrogen metabolites. Apocrine sweat glands, which produce pheromones and develop after puberty, are not involved in PHH. A third type of sweat gland, apoeccrine sweat glands, are only localized to the axillae and are involved in PHH of the axillae. 20 Sweating provides a means of important thermal regulation, allowing for the dissipation and evaporation of water to decrease body heat and temperature.

The sweat response is regulated by the autonomic nervous system, specifically the SNS via cholinergic neurons. In PHH, this system is thought to be dysregulated due to neurogenic overactivity or hyperexcitability. However, the exact pathophysiology of this remains unclear. 19 , 20 It is estimated that 30–65% of patients with PHH have a positive family history. 18 Whilst evidence suggests an autosomal dominant inheritance with partial penetrance and variable clinical presentation, it remains unclear whether PHH is purely genetic or multifactorial in origin. 21 Genetic studies have identified several loci potentially associated with primary focal HH, including 14q11.2–q13, 2q31.1, 1q41–1q42.3, 2p14–2p13.3, 2q21.2–2q23.3 and 15q26.3. 22 – 24 Additionally, mouse model studies have implicated several genes in PHH, such as AQP5 (encoding aquaporin 5), ITPR2 (encoding inositol 1,4,5-trisphosphate receptor type 2) and FoxA1 . 21 Certain environmental factors, such as stress and anxiety, can worsen the sweating in PHH. 25 One characteristic of PHH that may differ from SHH is that sweating only occurs when patients are awake. 26

When making a diagnosis of PHH, SHH must be ruled out and includes a wide range of potential causes such as endocrine, infectious, neurological, psychiatric, cardiovascular, dermatological, respiratory, gastrointestinal, haematological, musculoskeletal, physiological and autoimmune/autoinflammatory conditions, malignant disease or medications. 27 These categories and corresponding conditions are summarized in Table 1 . 15 , 28 – 54 , 55 – 83

Histopathology

Eccrine sweat glands in patients with PHH are histopathologically identical to unaffected individuals and there is no increase in the number of glands. However, sympathetic ganglia of patients with PHH may be larger on histopathological observation, suggesting hyperfunctioning of sweat glands rather than hypertrophy. 19

Clinical manifestations

As mentioned above, HH can be classified as PHH/essential (idiopathic) or SHH. The terms primary, essential and idiopathic HH are all synonymous. 84 HH can further be classified by distribution, with SHH being generalized and affecting the whole body, and PHH being focal, affecting a specific location of the body. Rzany et al. proposed the terms ‘primary focal HH’ when only one body site is affected and ‘primary multifocal HH’ when two or more body sites are affected. 84 PHH is typically focal, with the most common anatomical regions being palms/soles, axillae, face, trunk and genital area. 85 One study found that 80.4% of patients had palmoplantar involvement, 62.7% of patients had axillary involvement, 19.6% had truncal involvement, 17.6% had genital involvement and 16.7% had craniofacial involvement. 86

PHH is typically focal, most commonly affecting (in descending order) palms/soles (palmoplantar), axillae, trunk, genital area and face/head (craniofacial). PHH is often bilateral/symmetric but can be asymmetric and is often associated with a family history when presenting in a patient with younger onset. 86 Primary multifocal HH occurs when there are two or more focal areas affected. The most common presentation is of three total body sites affected (45.1% of patients), followed by two (41.2% of patients), four (8.8% of patients) and five (5.9% of patients). 86 Often, sweating will be present for at least 6 months, is absent during sleep, and is associated with increased morbidity and decreased quality of life. 86

Excessive sweating can cause cold, clammy skin and compromise the skin barrier, leading to maceration and a higher risk of cutaneous infections, including erythrasma, impetigo, pitted keratolysis, dermatophytosis (tinea pedis/cruris, onychomycosis), candidiasis and HPV-related lesions like verruca palmaris and plantaris. 16 , 87 Sweating may also trigger or worsen eczematous conditions, with PHH linked to irritant contact dermatitis, dyshidrotic eczema and atopic dermatitis. 88 , 89 Additional complications include bromhidrosis (malodour) and musculoskeletal issues such as poor posture due to attempts to conceal sweating. 90 , 91

Diagnosis

There are key clinical features that would aid in diagnosing PHH and a careful and complete history and physical examination is important in making a proper diagnosis. Questions that should be asked include pattern of sweating, age of symptom onset, provocative factors, duration, frequency, amount, time (night sweating) and distribution of sweating, family history of HH, and a review of symptoms related to secondary causes, which should include weight loss, fever and lymphadenopathy. 92 , 93 Secondary causes must be ruled out and targeted diagnostic testing should be based on clinical suspicions from the history and physical exam. 5 , 29 , 94 – 96 Specific diagnostic criteria for PHH include 6 months of visible, focal and excessive sweating, and at least four of the following: location in sweat gland-rich areas (palms, soles, axillae or craniofacial areas), symmetrical bilateral distribution, disruption of daily activities, occurring at least once or more per week, having an age of onset before 25, positive family history, and absence of nocturnal sweating. 29 , 94 , 95 , 97 Suspicious features of SHH include asymmetric, unilateral or generalized distribution of sweating with the absence of family history, occurring later in life (25 years or older) and an association with night sweats. 28

Measurements for PHH sweating also exist but are not commonly used clinically. However, they can help determine severity of sweating and are often used to guide treatment and management. 15 Measurement tests include the minor starch-iodine test, which colours affected regions purple; 92 , 98 the ninhydrin test that reacts with sweat to produce a colour that can be analysed digitally; 93 gravimetric testing, which weighs the sweat with filter paper; 92 , 99 , 100 the thermoregulatory sweat test, which measures sweating in a controlled laboratory environment; dynamic quantitative sudometry, which measures sweating over time; 101 – 103 and the electronic moisture meter, which detects moisture evaporation from the skin. 104 Other more subjective assessment tests based on patient symptom scores include the Hyperhidrosis Disease Severity Scale (HDSS), 5 , 93 , 104 the Hyperhidrosis Impact Questionnaire, 87 , 93 , 98 the Dermatology Life Quality Index (DLQI) questionnaire, 98 , 105 – 107 and the Medical Outcomes Trust Short Form 12 Health Survey. 87 , 93 , 108

The psychological impact of PHH is profound, affecting the quality of life, mental health, self-esteem, social interactions, relationships and career choices. 109 Nearly half (48%) of patients report poor or very poor quality of life, 110 with higher rates of depression and anxiety compared to the general population. 5 The psychological burden of PHH may be comparable to or greater than conditions like psoriasis and acne. 111 Common psychosocial effects include embarrassment (33.3%), shame (25.0%) and discomfort (16.7%). 110 Patients with palmar HH experience a mean productivity loss of 7.24%, resulting in substantial financial impact. 112 Managing PHH is time-consuming, with patients spending 15–60 min daily on symptom control and 50–70% changing clothes more than twice a day. 113 Affected individuals often avoid handshakes, have low self-esteem, withdraw socially and face job restrictions due to issues like rusting metal objects or wet paperwork. 90

Management

Management of PHH is challenging and often requires patients to trial multiple modalities, with options ranging from lifestyle changes to topical, systemic, device-based therapies, procedures and surgery. 114 – 119 All treatment modalities discussed in our review are summarized in Table 2 with an overview shown in Box 1 .

Treatment options for hyperhidrosis

Lifestyle, behavioural and adjunctive therapies

Avoidance of triggering and exacerbating factors

Use of moisture-wicking fabrics and cooling/absorbent devices

Topical therapies

Topical antiperspirants (e.g. aluminium chloride formulations)

Topical anticholinergics (e.g. glycopyrrolate, oxybutynin, sofpironium bromide, umeclidinium)

Topical botulinum toxin type A liposomal cream

Systemic therapies

Oral anticholinergic medications (e.g. glycopyrrolate, oxybutynin, methantheline bromide)

Other systemic agents (e.g. β-blockers, benzodiazepines, α2 agonists)

Device-based therapies

Iontophoresis

Microwave thermolysis

Ultrasound, fractional microneedle radiofrequency and laser treatments

Procedural and surgical interventions

Botulinum toxin injections

Excision, curettage and/or liposuction

Sympathectomy

Lifestyle, behavioural and adjunctive therapies

Lifestyle, behavioural and adjunctive therapies are recommended for all patients with PHH and include crowded areas, tight clothing, spicy foods, alcohol and triggering emotional stimulation. 114 Adjunctive therapies that fall into this category include using moisture-wicking sheets and pyjamas, portable body coolers, pens that can write in wet conditions, shirts with cooling devices, synthetic fabrics, masking sweat with underarm liners, dress shields, leather shoes, absorbent shoe insoles, foot powder and cotton/wool socks. 114 , 115 , 200 , 201 Lifestyle, behavioural and adjunctive therapies are recommended for all patients with PHH regardless of the type, can be initiated at any time, and are often used in conjunction with another treatment modality to support patients with PHH.

Topical therapies

Topical therapies are first-line treatments for PHH and include topical antiperspirants, topical anticholinergic and topical botulinum toxin (BTX) type A liposomal cream. 115 – 119 , 200

Topical antiperspirants

Topical antiperspirants primarily consist of metal salts, most notably aluminium salts such as aluminium chloride and aluminium zirconium, whilst other metals like vanadium and indium have also been used. 116 , 202 – 204 Amongst these, aluminium chloride hexahydrate is the most common and effective, particularly for mild to moderate PHH, and serves as a first-line, affordable option for primary focal HH, especially axillary and palmoplantar types (but including other forms such as craniofacial, which includes the scalp). 29 , 94 , 114 , 116 , 117 , 120 Concentrations range from 6% to 40%, delivered in various formulations (solutions, sticks, gels, creams), with over-the-counter products containing up to 12.5% aluminium chloride hexahydrate, whilst prescription formulations commonly include 20% aluminium chloride in ethyl alcohol. 114 , 116 , 117 , 120 , 121 Application is recommended nightly on dry skin for 6–8 hours, tapering to once weekly as symptoms improve (typically after >1 week). 93 , 114 – 118 , 202 Topical antiperspirants demonstrate high efficacy, with satisfaction rates of 94% for axillary, 84% for primary plantar, and 60% for primary palmar HH and sustained improvement in up to 87% of patients at 5 months. 114 , 117 , 202 , 204 The most common side-effects include skin irritation and itching (reported in 21% of patients), particularly in the axilla and with higher concentrations, as well as miliaria and irritant dermatitis. 93 , 114 , 116 , 147 , 205 – 208 These can be mitigated by spacing out applications, using lower concentrations, employing moisturizing agents, or applying triethanolamine or topical corticosteroids (e.g. 2.5% hydrocortisone); however, salicylic acid should be avoided as it is a known irritant. 93 , 114 , 116 , 121 , 147 , 205 – 208 Whilst concerns about links to Alzheimer disease and breast cancer have arisen from animal studies, no such associations have been demonstrated in humans. 114 , 118

Topical anticholinergics

Topical anticholinergics work by competitively blocking muscarinic receptors on eccrine sweat glands preventing the binding of acetylcholine and, subsequently, preventing sweating. Topical anticholinergics include topical glycopyrrolate, topical oxybutynin, topical sofpironium bromide and topical umeclidinium.

Topical glycopyrrolate

Topical glycopyrrolate is the most researched topical anticholinergic medication for PHH and is available in two forms: glycopyrronium bromide and glycopyrronium tosylate. Topical glycopyrrolate has been approved by the FDA for the treatment of primary axillary HH in patients older than 9 years of age. Concentrations and formulations include a 0.5–4% solution, gel, cream, spray or pads. Glycopyrronium tosylate can be delivered as a pre-moistened cloth applied daily with improvement expected after 1 week of use. 122 Randomized control studies (RCTs) and research have indicated that topical glycopyrrolate is a good treatment for axillary HH, palmar HH and craniofacial HH. For example, two RCTs 122 , 123 and one prospective study 124 utilizing a 4-week course of 2.4% glycopyrronium tosylate and 2% topical glycopyrronium bromide cream for primary axillary HH, resulted in significant reduction in sweating symptoms and improvement in scores on the DLQI and HDSS, with 60% of patients reporting sweating to be “much better” and results maintained at the 44-week follow-up. Another RCT of 497 patients with primary axillary HH showed clinical improvement (50% reduction in sweating and improvement in HDSS and DLQI scores) with 2.4% and 3.75% glycopyrronium tosylate cloths/wipes. 125 For primary palmar HH, 2.4% glycopyrronium tosylate cloth for 30 minutes without occlusion seems to be most effective in treating symptoms. 209 For primary craniofacial (including scalp) HH, two RCTs (39 and 25 patients, respectively) 126 , 127 showed a decrease in sweating symptoms and slight improvement in HDSS, whilst the other RCT (24 patients) also showed improvement with 2% topical glycopyrronium. 128 In a 44-week RCT of children (ages 9–16 years), the safety and efficacy of topical glycopyrrolate tosylate was maintained for the treatment of primary axillary HH, indicating its effectiveness for use in children older than 9 years of age. 129 Adverse effects associated with topical glycopyrrolate include skin irritation, pruritus, blurred vision, dysuria, headache, dizziness, sore throat, mydriasis, dry mouth, constipation and nasopharyngitis. 122 , 125 , 129 , 210

Topical oxybutynin

Topical oxybutynin is another topical anticholinergic that is well studied. It is used off-label for PHH. The most common formulations include 1–20% gel or lotion. An RCT of 53 patients showed that 10% topical oxybutynin gel resulted in improvement in DLQI and HDSS scores in 74% of patients after 30 days with primary axillary or palmoplantar HH. 130 Another RCT of 30 patients showed improvement in primary palmar HH with 1% oxybutynin gel and 1% oxybutynin nanoemulgel. 131 The largest phase III RCT (244 patients) with a 20% oxybutynin lotion showed reductions in sweat volume and improvement in symptoms in 53% of patients with primary palmar HH. 132 A pilot study in 10 children found a significant reduction in sweating for axillary HH with 3% topical oxybutynin. 133 Reported adverse events from these studies include side-effects related to headache, pruritus and erythema on the application site. 130

Topical sofpironium bromide

Topical sofpironium bromide is a recently developed anticholinergic medication that is being used in the treatment of PHH. Its use has been largely studied in primary axillary HH with concentrations of topical sofpironium gel at 5%, 10% and 15%. 134 It is applied daily with improvements seen as fast as 1 week with treatment durations in two separate phase III trials (281 and 185 patients with primary axillary HH, respectively) from 6 weeks to 52 weeks. 134 – 136 A phase II RCT showed improvement in DLQI scores along with reduced sweating symptoms from the use of topical sofpironium gel for primary axillary HH, with 5%, 10% and 15% showing stepwise improvement with increasing concentration in both DLQI and HDSS scores. 134 Adverse events include dry mouth, blurred vision, dermatitis, erythema and nasopharyngitis. 134 – 136

Topical umeclidinium

Only one phase IIa RCT has been conducted on topical umeclidinium at a concentration of 1.85% daily, resulting in a significant reduction of sweating and improvement in HDSS scores in 40% of patients with primary axillary HH after 2 weeks. The only adverse events noted were application site pain, bronchitis, headache and presyncope with evidence of systemic absorption due to measurable plasma levels in 78% of patients. 137

Topical BTX type A liposomal cream

One RCT in 20 patients with primary axillary HH, showed that daily application of topical BTX type A liposomal cream reduced sweating and resulted in improved HDSS scores at 2 and 8 weeks. No adverse effects were noted. 211 Its use in clinical settings for the treatment of PHH may become more relevant with continued research.

Systemic therapies

Systemic therapies for PHH are primarily in the form of oral anticholinergic drugs. 114 – 118 These medications are not approved by the FDA and are often reserved for treatment-resistant cases and for the treatment of generalized or multifocal PHH.

Oral anticholinergic medication

Oral anticholinergic medication functions by competitively inhibiting the muscarinic receptor acetylcholine binding site, preventing the production of sweat at eccrine sweat glands. 212 The most common oral systemic anticholinergic medications are glycopyrrolate, oxybutynin and methantheline bromide (used in Europe but not currently available in the USA).

Oral glycopyrrolate

Oral glycopyrrolate is another used oral anticholinergic medication in PHH. 138 , 139 In adults, the most common doses are between 0.5 mg and 3 mg once or twice daily, with children (approved for use in children above 11) typically using 2 mg daily. 115 , 138 , 139 Treatment efficacy is often achieved after 1 week and increases in doses may be required. 114 Oral glycopyrrolate has been shown to be an effective treatment in primary focal and multifocal HH with response rates in the range of 67–79% of patients. 140 The most common adverse events include dry mouth, impaired vision, dry eyes, headache, palpitations and urine retention. 140 , 212 Whilst it may be an effective medication, one-third of patients discontinue the medication due to these side-effects. 139 Absolute and relative contraindications to use include pyloric stenosis , paralytic ileus , myasthenia gravis , gastroesophageal reflux disease , cardiac insufficiency, closed-angle glaucoma and bladder outlet obstruction . 121 , 139

Oral oxybutynin

Oral oxybutynin is another anticholinergic medication for PHH. Typical doses in adults include 2.5–5 mg once or twice daily with typical total doses in the range of 5–10 mg a day and maximum doses as high as 20 mg, with improvement seen at 1 week and administered up to at least 6 weeks with ongoing maintenance. 114 , 138 , 141 , 142 Effective doses in children under the age of 14 years range from 2.5 to 10 mg daily. 143 In terms of effectiveness, oral oxybutynin relieved symptoms in 76.2% of patients and improved quality of life in 75.6% of patients. 140 The most commonly reported side-effects include dry mouth in 30–43% of adults and 53% of children as well as nausea, diarrhoea, gastroesophageal reflux, headache, dizziness, flushing, blurred vision, urinary retention, tiredness and constipation. 141 – 143

Methantheline bromide

Methantheline bromide is another oral anticholinergic used in PHH. In one RCT of 339 patients, after 4 weeks using a dose of 50 mg three times daily resulted in reduced primary axillary sweating and improved DLQI and HDSS scores. 144

Other systemic therapies

Other oral therapies used in the literature with limited data include β-blockers, benzodiazepines, α2-adrenergic receptor agonists, prostaglandin E2 inhibitors and calcium channel blockers. Benzodiazepines have been shown to help with anxiety-induced HH. 138 Prostaglandin E2 inhibitors, such as indomethacin, may block prostaglandin E2-induced sweating in vitro. 114 , 121 Calcium channel blockers may reduce sweating by inhibiting calcium-dependent acetylcholine release. 114 The most widely studied are α2-adrenergic receptor agonists. Clonidine has been used in generalized and paroxysmal localized PHH and works by reducing sympathetic activity on eccrine sweat glands. 145 Dosages that have been used include 0.1 or 0.15 mg twice daily with side-effects including dry mouth, dizziness , constipation and sedation. 146 The aforementioned medications may be useful in certain cases of patients with PHH but are not widely used and more research is needed to determine their validity.

Device-based therapy

Device-based therapy includes iontophoresis, microwave thermolysis, ultrasound, fractional microneedle radiofrequency and laser treatments. 114 – 118

Iontophoresis

Iontophoresis involves immersing the affected skin in tap water or an ionized solution, through which a low-voltage electric current is applied. This current repels hydrogen ions, leading to blockage of the sweat glands by altering the electrochemical gradient, lowering the local pH and potentially inhibiting SNS activity. These changes, including glandular damage, acidification and SNS inhibition, collectively result in obstruction of sweat ducts and a reduction in sweat production. 146 , 147 Iontophoresis is approved by the FDA as a first-line treatment for primary palmar and plantar HH and used for primary axillary HH by special electrode pads. 146 , 148 Iontophoresis is not generally used or recommended for craniofacial (including scalp) HH as it can be technically challenging and there may be a high risk of injury. In the USA, iontophoresis machines are only available by prescription (RA Fischer, RA Fischer Co., Northridge, CA, USA; Hidrex, Hidrex USA, LLC, Austin, TX, USA; Drionic, General Medical Co., Los Angeles, CA, USA; and Dermadry, Dermadry Laboratories Inc., Montreal, QC, Canada). Iontophoresis is performed three to four times per week by submerging the affected area (palms, soles or axillae) for 15–40 min at a current of 15–20 mA. Patients see improvement at around 3–4 weeks with transition to maintenance therapy at once per week. 95 , 146 , 149 There is higher compliance with at-home devices and iontophoresis is effective in 80% of cases. 147 , 150 , 151 Aluminium chloride, anticholinergics and BTX may be added as a medium to the tap water. Topical and/or systemic agents can also be added as combination therapy to improve the effects of iontophoresis. 89 , 139 , 214 – 219 Contraindications to iontophoresis include pregnancy, substantial metal implants, cardiac conditions, epilepsy and implantable electronic devices, including pacemakers. 220 – 223 Side-effects include discomfort (shock), dryness (mouth and throat), paraesthesias, erythema, transient vesiculations, skin irritation, dermatitis and asteatosis. 220 , 222 , 224 Decreasing the frequency and intensity of iontophoresis and application of moisturizers and corticosteroid cream can help reduce these side-effects. 121 , 225 , 226

Microwave thermolysis

Microwave thermolysis is a non-surgical procedure that uses microwave electromagnetic radiation to heat and induce deep dermal fibrosis and cellular thermolysis of eccrine sweat glands, irreversibly destroying them. 152 , 153 One medical device is approved by the FDA (MiraDry (Miramar Labs, Sunnyvale, CA, USA) for the treatment of primary axillary HH. 153 Microwave thermolysis showed 90% efficacy that persisted for more than 12 months in one study, and 80% efficacy in a statistically significant decrease in sweating severity and symptoms by improvement of HDSS at 1, 6 and 12 months of follow-up in another study. 152 , 153 The largest RCT evaluating MiraDry in 81 patients showed that 62% of patients who received three treatments achieved 75% efficacy in reduction of gravimetric-measured sweat production. 153 The machine has not been studied in paediatric patients and is approved only for patients 18 years and older. 115 Side-effects were generally mild to moderate, with short-term effects, such as pain, oedema, erythema, rash, dermatitis, ecchymosis, axillary tenderness, numbness and temporary altered sensation resolving within 3 months, whilst long-term effects included compensatory HH, subcutaneous nodules, permanent patchy alopecia and, rarely, brachial plexus injury leading to transient median and ulnar neuropathy. 152 , 153 , 224 , 227 – 229

Ultrasound

Ultrasound therapy is a device-based therapy that is not commonly used in clinical practice but has been used as an off-label treatment for primary axillary sweating. It involves the use of low levels of focused thermal injury resulting in collagen remodelling in sweat glands. 114 , 154 Specifically, an ultrasound system (VASER, SoltaMedical, Inc., Hayward, CA, USA) approved by the FDA for body contouring and soft tissue emulsification showed an 80% reduction in sweating and 90% satisfaction in one study. 155 , 156 Whilst minimally invasive, it has not been tested in the paediatric patient population. 115 Adverse events related to side-effects include temporary tenderness, redness, numbness and bruising. 115 , 157

Fractional microneedle radiofrequency

Fractional microneedle radiofrequency involves the insertion of microneedles into the skin, particularly eccrine sweat glands, with subsequent emission of bipolar thermal energy causing destruction of the sweat gland. 118 , 158 , 159 Whilst not routinely used clinically, the literature indicates that patients with primary axillary HH showed improvements in HDSS scores and reduction of sweating at 6 weeks, 9 weeks and 21 weeks. 159 Adverse events included transient erythema, pain, swelling, desquamation, burning sensation, post-inflammatory hyperpigmentation as well as mild pain, swelling and redness. 160 , 161

Laser treatments

Laser treatments for PHH are not routinely used in a clinical setting but have shown some success in the literature. 114 These include the 1064 and 1320 nm neodymium-doped yttrium aluminium garnet (Nd:YAG) laser and diode lasers (800, 924 and 975 nm). 162 – 166 In an RCT of 100 patients, a diode-powered laser with a wavelength of 975 nm with 20 W alone and wavelengths of 924 and 975 nm simultaneously, both showed improvement in HDSS scores and reduced sweating at 1 and 12 months for primary axillary HH. 165 An RCT of six patients using the Nd:YAG laser demonstrated that the 1064-nm wavelength reduced axillary sweating after 1–3 months. 166 Adverse events related to side-effects include local pain, sensation loss, hair reduction, hematoma, oedema, burns, skin erosion and compensatory HH. 162 – 166

Small procedures

Small procedures are non-device-based local procedures that are potential treatment modalities for PHH. These include BTX injections, excision, curettage, liposuction or a combination of these treatments. All procedures have a risk of compensatory sweating resulting in worse symptoms. 114 – 119

BTX injections

BTX injections, specifically BTX-A and BTX-B are the two most commonly used for PHH, and the FDA has approved onabotulinum toxin A for severe primary axillary HH treatment. 121 BTX is a protein produced by gram-positive bacteria Clostridium botulinum and works by temporarily blocking the release of neuronal acetylcholine from the presynaptic junction (through preventing exocytosis of vesicles) of the SNS, preventing the action of sweating. 117 , 118 , 121 In the USA, there are three BTX-A formulations available, namely onabotulinum (Botox; Allergan , Irvine, CA, USA), incobotulinum (Xeomin; Merz Pharmaceuticals, Greensboro, NC, USA) and abobotulinum (Dysport; Galderama Laboratories, Fort Worth, TX, USA), and one BTX-B formulation available for PHH (rimabotulinum, Myobloc; Solstice Neurosciences, Louisville, KY, USA). 230 BTX injections have been studied in primary axillary (FDA approved in 2004), palmoplantar and craniofacial (including scalp) HH in adults, with off-label use in paediatric patients. 114 , 119 One double-blind, placebo-controlled trial with 320 patients 167 showed a response rate of 94% with 50 units of onabotulinum toxin A per axilla, whilst other studies 167 – 169 showed improved outcomes with 100–200 units per axilla, with improvement seen within 2–4 days after treatment and sustained for 3–9 months, with patients often requiring 1–2 onabotulinum toxin A injections annually. 114 , 117 Different doses may be required, with higher doses for primary palmoplantar HH compared to primary craniofacial (including scalp) HH. For example, one study indicated that injections for primary palmar HH required 50–100 units of onabotulinum toxin A or 100–240 units of abobotulinum toxin A per hand injected 1–1.5 cm apart. 230 BTX is usually placed at the dermal-subcutaneous junction, 2.5 mm below the skin with 10–20 injections administered 1–2 cm apart. 114 One study of paediatric patients with primary axillary HH found that two treatment cycles with BTX-A spaced 2–8 weeks apart found a 2-point improvement in HDSS scores and significantly reduced sweating symptoms. 170 Treatment of primary axillary HH shows 82–87% efficacy and up to 98% satisfaction rates, followed by primary plantar HH with 80–90% efficacy reported in various studies, and primary craniofacial (including scalp) HH showing efficacy rates of up to 92% and satisfaction rates of 87% but may have the highest potential for side-effects with many reporting craniofacial defects. 167 – 174 BTX-B has a quicker response time but has a reduced period of action, a broader side-effect profile and is more painful to administer. 121 , 231 – 233 The most common complaint with treatment is pain, particularly in the palmar and plantar regions, with discomfort lasting an average of 2.4 days but potentially extending up to 10 days. Techniques to reduce these side-effects during injections include needle-free anaesthesia, cryoanalgesia, vibration analgesia, pocketed microneedles, topical anaesthetics, dilution with lidocaine, sedation, intravenous regional anaesthesia and nerve blocks. For palmar and plantar botulinum injections, topical anaesthetic agents or ice can provide relief, whilst ulnar, median and radial nerve blocks or a modified Bier block are effective for the palms, and posterior tibial and sural nerve blocks may be used for the plantar region. 117 , 121 , 234 – 247 Complications are rare and generally mild but include headaches, myalgia, itching and, more rarely, compensatory sweating in previously unaffected areas. 100 , 121 , 167 , 168 , 248 – 250

Local excision, curettage or liposuction

Local excision for PHH may be warranted when conservative treatments have failed. 251 Side-effects include scarring and restriction in arm movement. 175 , 176 , 184 , 251 , 252 No studies in paediatric patients have been conducted on excisional procedures.

Excisions with either a curette, liposuction cannula or both can be performed for permanent removal of axillary eccrine and apocrine sweat glands when medical management has failed. 114 , 118 Excision with curettage is slightly more effective than liposuction but has an increased risk of scarring and morbidity. 175 Patient satisfaction is high due to permanent removal of sweat glands. However, relapses are possible, outcomes are dependent on the skill of the surgeon, and there are several side-effects. No studies have been conducted in paediatric patients. 115 Curettage reduces the risk of scarring compared to other procedural methods but carries a risk of complications, including bleeding, pain, bruising, skin erosion, infection, ecchymosis, hyperpigmentation, seroma, damage to the brachial plexus, dysaesthesia, hair loss, recurrence of HH and compensatory sweating, along with other potential side-effects common to skin injuries such as scarring, hyperpigmentation and dysaesthesia. 175 – 183

Surgical interventions

Surgical interventions include sympathectomy, sympathicolysis and video-assisted thoracoscopic sympathectomy, including endoscopic thoracic sympathectomy. These procedures remove tissue through bilateral sympathectomy or ganglionectomy via transecting, resecting, cutting, ablating or clipping the sympathetic trunk at the T1–T5 level. 114 – 119 , 185 , 186 This results in denervation of sweat glands and subsequent decrease in sweating. 187 Sympathectomy is often a last resort treatment for PHH, with its effectiveness seen best in upper extremity PHH, specifically primary palmar HH. 115 Sympathectomy has better results in patients with early-onset PHH (before age 25 years), a body mass index of <28 kg/m 2 and in the absence of nocturnal sweating, serious comorbidities and bradycardia. 187 Sympathectomy is effective in 68–100% of cases, though satisfaction rates tend to decline over time, with patients with primary palmar HH reporting the highest satisfaction. 188 – 190 When ETS is used for primary palmar HH, it targets the T2 and T3 ganglia, whilst craniofacial (including the scalp) ETS is done above the T3 level, axillary at the T3/4 level, and plantar at L3/L4. 114 , 191 Postoperative complications may include pneumothorax, haemothorax, subcutaneous emphysema, intrathoracic bleeding, hematoma, paraesthesia, upper limb neurological impairment, stellate ganglion injury leading to Horner syndrome (ptosis, miosis and anhidrosis), hyperthermia, phrenic nerve injury, bradycardia, sensory and/or motor limb changes, and scarring. Additionally, postoperative pain, compensatory sweating and recurrent HH are potential concerns. 184 , 185 , 190 – 197 Recurrent primary focal HH and compensatory sweating of the abdomen, back, legs and gluteal region are also common long-term effects. 187 , 198 , 199 Sympathectomy has not been studied in the paediatric population, and given the risks involved with anaesthesia, the procedure itself, and its irreversibility, its use requires caution and consideration in only the most severe cases of refractory PHH. 115

Conclusion

It is important for clinicians to recognize HH and to differentiate primary from secondary forms to ensure that patients receive an appropriate diagnostic evaluation and tailored management. Given that HH can significantly impact both physical comfort and psychological well-being, early identification is essential to minimize unnecessary investigations and to implement effective treatment strategies.

For patients with mild HH, conservative measures, such as lifestyle modifications and the use of topical antiperspirants (e.g. aluminium chloride formulations), can provide adequate symptom relief. In contrast, patients with moderate to severe or refractory HH may benefit from additional modalities, including topical anticholinergics, device-based therapies (such as iontophoresis, microwave thermolysis and laser treatments), systemic anticholinergic agents and BTX injections. Although surgical interventions like sympathectomy are generally reserved for cases that do not respond to less invasive treatments, its use remains somewhat controversial.

Ultimately, a multidisciplinary and individualized approach is essential to optimizing both the physical and psychosocial outcomes of patients with HH. Further well-designed studies are warranted to refine these therapeutic strategies and to better define the long-term safety and efficacy of emerging treatment modalities.

Acknowledgements

None.

Footnotes

Contributions: MM is the principal author. AKCL and JML are co-authors who contributed and helped with the drafting of this manuscript. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work and have given their approval for this version to be published.

Disclosure and potential conflicts of interest: AKCL is an associate editor of Drugs in Context . MM and JML took part in a non-funded survey study (investigator initiated) of response to treatment with DermaDry. JML also received an iontophoresis machine for clinic from DermaDry. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors is available for download at: https://www.drugsincontext.com/wp-content/uploads/2025/05/dic.2025-3-2-COI.pdf

Funding declaration: There was no funding associated with the preparation of this article.

Correct attribution: Copyright © 2025 Maazi M, Leung AKC, Lam JM. https://doi.org/10.7573/dic.2025-3-2 . Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0.

Article URL: https://www.drugsincontext.com/primary-hyperhidrosis-an-updated-review

Provenance: Invited; externally peer reviewed.

Drugs in Context is published by BioExcel Publishing Ltd. Registered office: 6 Green Lane Business Park, 238 Green Lane, New Eltham, London, SE9 3TL, UK.

BioExcel Publishing Limited is registered in England Number 10038393. VAT GB 252 7720 07.

For all manuscript and submissions enquiries, contact the Editorial office editorial@drugsincontext.com

For all permissions, rights, and reprints, contact David Hughes david.hughes@bioexcelpublishing.com

References

1. Benson RA, Palin R, Holt PJ, Loftus IM. Diagnosis and management of hyperhidrosis. BMJ. 2013;347:f6800. doi: 10.1136/bmj.f6800.

2. McConaghy JR, Fosselman D. Hyperhidrosis: management options. Am Fam Physician. 2018;97(11):729–734.

3. Lima SO, Aragão JF, Machado JN, Almeida KB, Menezes LM, Santana VR. Research of primary hyperhidrosis in students of medicine of the State of Sergipe, Brazil. An Bras Dermatol. 2015;90(5):661–665. doi: 10.1590/abd1806-4841.20153859.

4. Adar R, Kurchin A, Zweig A, Mozes M. Palmar hyperh-idrosis and its surgical treatment: a report of 100 cases. Ann Surg. 1977;186(1):34–41. doi: 10.1097/00000658-197707000-00006.

5. Strutton DR, Kowalski JW, Glaser DA, Stang PE. US prevalence of hyperhidrosis and impact on individuals with axillary hyperhidrosis results from a national survey. J Am Acad Dermatol. 2004;51(2):241–248. doi: 10.1016/j.jaad.2003.12.040.

6. Li X, Chen R, Tu YR, Lin M, Lai FC, Li YP. Epidemiological survey of primary palmar hyperhidrosis in adolescents. Chin Med J. 2007;120(24):2215–2217.

7. Tu YR, Li X, Lin M, Lai FC, Li YP, Chen JF. Epidemiological survey of primary hyperhidrosis in adolescents in Fuzhou of People’s Republic of China. Eur J Cardiothorac Surg. 2007;31(4):737–739. doi: 10.1016/j.ejcts.2007.01.020.

8. Felini R, Demarchi AR, Fistarol ED, Matiello M, Delorenze LM. Prevalence of hyperhidrosis in the adult population of Blumenau-SC, Brazil. An Bras Dermatol. 2009;84(4):361–366. doi: 10.1590/S0365-05962009000400007.

9. Chu D, Chen RC, Lee CH, Yang NP, Chou P. Incidence and frequency of endoscopic sympathectomy for the treatment of hyperhidrosis palmaris in Taiwan. Kaohsiung J Med Sci. 2010;26(3):123–129. doi: 10.1016/S1607-551X(10)70018-8.

10. Westphal FL, de Carvalho MA, Lima LC, de Carvalho BC, Padilla R, Araújo KK. Prevalence of hyperhidrosis among medical students. Rev Col Bras Cir. 2011;38(6):392–397. doi: 10.1590/S0100-69912011000600005.

11. Stefaniak T, Tomaszewski KA, Proczko-Markuszewska M, Idestal A, Royton A, Abi-Khalil C. Is subjective hyperhidrosis assessment sufficient enough? Prevalence of hyperhidrosis among young Polish adults. J Dermatol. 2013;40(10):819–823. doi: 10.1111/1346-8138.12238.

12. Fujimoto T, Kawahara K, Yokozeki H. Epidemiological study and considerations of primary focal hyperhidrosis in Japan from questionnaire analysis. J Dermatol. 2013;40(11):886–890. doi: 10.1111/1346-8138.12258.

13. Augustin M, Radtke MA, Herberger K, Kornek T, Heigel H, Schaefer I. Prevalence and disease burden of hyperhidrosis in the adult population. Dermatology. 2013;227(1):10–13. doi: 10.1159/000351292.

14. Lai FC, Tu YR, Li YP, Li X, Lin M, Chen JF. Nationwide epidemiological survey of primary palmar hyperhidrosis in the People’s Republic of China. Clin Auton Res. 2015;25(2):105–108. doi: 10.1007/s10286-014-0259-5.

15. Nawrocki S, Cha J. The etiology, diagnosis, and management of hyperhidrosis: a comprehensive review: etiology and clinical work-up. J Am Acad Dermatol. 2019;81(3):657–666. doi: 10.1016/j.jaad.2018.12.071.

16. Walling HW. Primary hyperhidrosis increases the risk of cutaneous infection: a case-control study of 387 patients. J Am Acad Dermatol. 2009;61(2):242–246. doi: 10.1016/j.jaad.2009.02.038.

17. Liu Y, Bahar R, Kalia S, et al. Hyperhidrosis prevalence and demographic characteristics in dermatology outpatients in Shanghai and Vancouver. PLoS One. 2016;11(4):e0153719. doi: 10.1371/journal.pone.0153719.

18. Nastase F, Verenca MC, Niculet E, et al. Primary hyperhidrosis in children: a retrospective study and a short review. Life. 2024;14:645. doi: 10.3390/life14050645.

19. Romero FR, Haddad GR, Miot HA, Cataneo DC. Palmar hyperhidrosis: clinical, pathophysiological, diagnostic and therapeutic aspects. An Bras Dermatol. 2016;91(6):716–725. doi: 10.1590/abd1806-4841.20165358.

20. Schick CH. Pathophysiology of hyperhidrosis. Thorac Surg Clin. 2016;26(4):389–393. doi: 10.1016/j.thorsurg.2016.06.002.

21. Parveen A, Abbas S, Mehmood N, et al. Primary hyperhidrosis: from a genetics point of view. J Family Med Prim Care. 2023;12(12):3028–3032. doi: 10.4103/jfmpc.jfmpc_1568_22.

22. Higashimoto I, Yoshiura K, Hirakawa N, et al. Primary palmar hyperhidrosis locus maps to 14q11.2-q13. Am J Med Genet A. 2006;140(6):567–572. doi: 10.1002/ajmg.a.31127.

23. Chen J, Lin M, Chen X, et al. A novel locus for primary focal hyperhidrosis mapped on chromosome 2q31.1. Br J Dermatol. 2015;172(4):1150–1153. doi: 10.1111/bjd.13383.

24. Schote AB, Schiel F, Schmitt B, et al. Genome-wide linkage analysis of families with primary hyperhidrosis. PLoS One. 2020;15(12):e0244565. doi: 10.1371/journal.pone.0244565.

25. Gross KM, Schote AB, Schneider KK, Schulz A, Meyer J. Elevated social stress levels and depressive symptoms in primary hyperhidrosis. PLoS One. 2014;9:e92412. doi: 10.1371/journal.pone.0092412.

26. Vannucci F, Araújo JA. Thoracic sympathectomy for hyperhidrosis: from surgical indications to clinical results. J Thorac Dis. 2017;9(Suppl 3):S178–S192. doi: 10.21037/jtd.2017.04.04.

27. Behinaein P, Gavagan K, Waitzman J, Pourang A, Potts G. A review of the etiologies and key clinical features of secondary hyperhidrosis. Am J Clin Dermatol. 2025;26(1):97–108. doi: 10.1007/s40257-024-00908-6.

28. Akbaş A, Kilinç F. Investigation on aetiological factors in patients with hyperhidrosis. Cutan Ocul Toxicol. 2018;37(4):344–349. doi: 10.1080/15569527.2018.1466897.

29. Walling HW. Clinical differentiation of primary from secondary hyperhidrosis. J Am Acad Dermatol. 2011;64(4):690–695. doi: 10.1016/j.jaad.2010.03.013.

30. Serdar ZA, Altunay IK, Yasar S, Kayaoglu S, Günes P. Localized crossed hyperhidrosis and the coexistence of thyroid gland disease. J Dermatol. 2010;37(6):554–558. doi: 10.1111/j.1346-8138.2009.00742.x.

31. Sneppen SB, Main KM, Juul A, et al. Sweat secretion rates in growth hormone disorders. Clin Endocrinol. 2000;53(5):601–608. doi: 10.1046/j.1365-2265.2000.01141.x.

32. Lause M, Kamboj A, Fernandez Faith E. Dermatologic manifestations of endocrine disorders. Transl Pediatr. 2017;6(4):300–312. doi: 10.21037/tp.2017.09.08.

33. Astman N, Friedberg I, Wikstrom JD, et al. The association between obesity and hyperhidrosis: a nationwide, cross-sectional study of 2.77 million Israeli adolescents. J Am Acad Dermatol. 2019;81(2):624–627. doi: 10.1016/j.jaad.2019.01.019.

34. Mirmirani P, Carpenter DM. Skin disorders associated with obesity in children and adolescents: a population-based study. Pediatr Dermatol. 2014;31(2):183–190. doi: 10.1111/pde.12271.

35. Collercandy N, Thorey C, Diot E, et al. When to investigate for secondary hyperhidrosis: data from a retrospective cohort of all causes of recurrent sweating. Ann Med. 2022;54(1):2089–2101. doi: 10.1080/07853890.2022.2102675.

36. Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. J Clin Oncol. 1989;7(11):1630–1636. doi: 10.1200/JCO.1989.7.11.1630.

37. Robertshaw D. Hyperhidrosis and the sympatho-adrenal system. Med Hypotheses. 1979;5(3):317–322. doi: 10.1016/0306-9877(79)90011-2.

38. Ciuche A, Nistor C, Pantile D, Marin D, Tudose A. Spontaneous pneumothorax in a case of pulmonary Langerhans cell histiocytosis. Maedica. 2011;6(3):204–209.

39. Criscuolo M, Fianchi L, Maraglino AME, Pagano L. Mastocytosis: one word for different diseases. Oncol Ther. 2018;6(2):129–140. doi: 10.1007/s40487-018-0086-2.

40. Aqui TLB, Patel NK, Zhang Y, Kubomoto S. Ipsilateral facial hyperhidrosis in a patient with squamous cell carcinoma of the lung. Cureus. 2022;14(5):e24832. doi: 10.7759/cureus.24832.

41. Waran E. Doctor, I am sweating on just one side of my body: unilateral hyperhidrosis associated with mesothelioma. Clin Case Rep. 2016;4(5):533–534. doi: 10.1002/ccr3.557.

42. Seline MPC, Jaskierny MDJ. Cutaneous metastases from a chondroblastoma initially presenting as unilateral palmar hyperhidrosis. J Am Acad Dermatol. 1999;40(2):325–327. doi: 10.1016/S0190-9622(99)70477-9.

43. Pranteda G, Carlesimo M, Pranteda G, et al. Pitted keratolysis, erythromycin, and hyperhidrosis: pitted keratolysis and hyperhidrosis. Dermatol Ther. 2014;27(2):101–104. doi: 10.1111/dth.12064.

44. Arbune M, Iancu AV, Lupasteanu G, et al. A challenge of COVID-19: associated infective endocarditis with Streptococcus gordonii in a young immunocompetent patient. Medicina. 2021;57(12):1298. doi: 10.3390/medicina57121298.

45. Gauer R, Forbes D, Boyer N. Sepsis: diagnosis and management. Am Fam Physician. 2020;101(7):409–418.

46. Luies L, du Preez I. The echo of pulmonary tuberculosis: mechanisms of clinical symptoms and other disease-induced systemic complications. Clin Microbiol Rev. 2020;33(4):e00036–20. doi: 10.1128/CMR.00036-20.

47. Ismail D, Madhwapathi V, Ladoyanni E. Focal hyperhidrosis associated with recurrent urinary tract infections. Case Rep Dermatol Med. 2016;2016:3842984. doi: 10.1155/2016/3842984.

48. Cheshire WP, Fealey RD. Drug-induced hyperhidrosis and hypohidrosis: incidence, prevention, and management. Drug Saf. 2008;31(2):109–126. doi: 10.2165/00002018-200831020-00002.

49. Shamsuddin AKM, Reddy MM, Quinton PM. Iontophoretic β-adrenergic stimulation of human sweat glands: possible assay for cystic fibrosis transmembrane conductance regulator activity in vivo. Exp Physiol. 2008;93(8):969–981. doi: 10.1113/expphysiol.2008.042283.

50. Yoda T, Crawshaw LI, Nakamura M, et al. Effects of alcohol on thermoregulation during mild heat exposure in humans. Alcohol. 2005;36(3):195–200. doi: 10.1016/j.alcohol.2005.09.002.

51. West R, Gossop M. Overview: a comparison of withdrawal symptoms from different drug classes. Addiction. 1994;89(11):1483–1489. doi: 10.1111/j.1360-0443.1994.tb03747.x.

52. Rowane M, Valencia R, Schend J, Jhaveri D, Hostoffer R. Something to sweat about: two cases of dupilumab-induced hyperhidrosis and bromhidrosis. Allergy Rhinol. 2020:11. doi: 10.1177/2152656720927703.

53. Mizukawa Y, Sato Y, Ohyama M, Shiohara T. Restoration of sweating disturbance in atopic dermatitis treated with dupilumab. J Dermatol Sci. 2020;100(1):79–81. doi: 10.1016/j.jdermsci.2020.08.007.

54. Margheim A, Schadt CR. Unilateral hyperhidrosis secondary to brainstem meningioma producing mass effect. Dermatol Online J. 2019;25(11):13030/qt905497s9. doi: 10.5070/D32511046144.

55. Özdemir O, Özçakar L. Thoracic outlet syndrome: another cause for unilateral palmar hyperhidrosis. Clin Rheumatol. 2007;26(8):1375–1376. doi: 10.1007/s10067-006-0400-5.

56. Lamotte G, Sandroni P, Cutsforth-Gregory JK, et al. Clinical presentation and autonomic profile in Ross syndrome. J Neurol. 2021;268(10):3852–3860. doi: 10.1007/s00415-021-10531-8.

57. Rodrigues Masruha M, Lin J, Arita JH, et al. Spontaneous periodic hypothermia and hyperhidrosis: a possibly novel cerebral neurotransmitter disorder. Dev Med Child Neurol. 2011;53(4):378–380. doi: 10.1111/j.1469-8749.2010.03854.x.

58. Chopra KF, Evans T, Severson J, Tyring SK. Acute varicella zoster with postherpetic hyperhidrosis as the initial presentation of HIV infection. J Am Acad Dermatol. 1999;41(1):119–121. doi: 10.1016/S0190-9622(99)70419-6.

59. Gan J, Liu S, Wang XD, et al. The association between hyperhidrosis and dementia: a community-based research. J Alzheimers Dis. 2021;84(4):1657–1667. doi: 10.3233/JAD-210611.

60. Van Wamelen DJ, Leta V, Podlewska AM, et al. Exploring hyperhidrosis and related thermoregulatory symptoms as a possible clinical identifier for the dysautonomic subtype of Parkinson’s disease. J Neurol. 2019;266(7):1736–1742. doi: 10.1007/s00415-019-09325-w.

61. Mold JW. Associations between night sweats and other sleep disturbances: an OKPRN study. Ann Fam Med. 2006;4(5):423–426. doi: 10.1370/afm.554.

62. Arnardottir ES, Janson C, Bjornsdottir E, et al. Nocturnal sweating — a common symptom of obstructive sleep apnoea: the Icelandic sleep apnoea cohort. BMJ Open. 2013;3(5):e002795. doi: 10.1136/bmjopen-2013-002795.

63. Klein SZ, Hull M, Gillard KK, Peterson-Brandt J. Treatment patterns, depression, and anxiety among US patients diagnosed with hyperhidrosis: a retrospective cohort study. Dermatol Ther. 2020;10(6):1299–1314. doi: 10.1007/s13555-020-00439-y.

64. Davidson JRT, Foa EB, Connor KM, Churchill LE. Hyperhidrosis in social anxiety disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26(7–8):1327–1331. doi: 10.1016/S0278-5846(02)00297-X.

65. Pompili M, Ducci G, Galluzzo A, Rosso G, Palumbo C, De Berardis D. The management of psychomotor agitation associated with schizophrenia or bipolar disorder: a brief review. Int J Environ Res Public Health. 2021;18(8):4368. doi: 10.3390/ijerph18084368.

66. Gokhroo RK, Ranwa BL, Kishor K, et al. Sweating: a specific predictor of ST-segment elevation myocardial infarction among the symptoms of acute coronary syndrome: sweating in myocardial infarction (SWIMI) study group. Clin Cardiol. 2016;39(2):90–95. doi: 10.1002/clc.22498.

67. Slavich M, Falasconi G, Guarnaccia A, et al. Hyperhidrosis: the neglected sign in heart failure patients. Am J Cardiovasc Dis. 2021;11(5):635–641.

68. Laeng RH, Heilbrunner J, Itin PH. Late-onset eccrine angiomatous hamartoma: clinical, histological, and imaging findings. Dermatology. 2001;203(1):70–74. doi: 10.1159/000051709.

69. Sanusi T, Li Y, Sun L, Wang C, Zhou Y, Huang C. Eccrine angiomatous hamartoma: a clinicopathological study of 26 cases. Dermatology. 2015;231(1):63–69. doi: 10.1159/000381421.

70. Lasso Andrade FA, Cadena Arteaga JA, Echeverry Morillo VL, et al. Blue rubber bleb nevus syndrome: presentation of a case and review of the literature. Radiol Case Rep. 2021;16(8):2003–2006. doi: 10.1016/j.radcr.2021.04.086.

71. Shah S, Boen M, Kenner-Bell B, Schwartz M, Rademaker A, Paller AS. Pachyonychia congenita in pediatric patients: natural history, features, and impact. JAMA Dermatol. 2714;150(2):146–153. doi: 10.1001/jamadermatol.2013.6448.

72. Martin-Gorgojo A, Sanchez-Carpintero I, Ruiz-Rodriguez R, Enguita-Valls AB. Eccrine nevus in the forearm of a 16-year-old presenting as unilateral hyperhidrosis: a clinicopathological correlation paradigm. Dermatopathology. 2021;8(3):446–449. doi: 10.3390/dermatopathology8030047.

73. Parslew R, Lewis-Jones MS. Localized unilateral hyperhidrosis secondary to an eccrine naevus. Clin Exp Dermatol. 1997;22(5):246–247. doi: 10.1111/j.1365-2230.1997.tb01080.x.

74. Baskan EB, Karli N, Baykara M, Cikman S, Tunali S. Localized unilateral hyperhidrosis and neurofibromatosis type 1: case report of a new association. Dermatology. 2005;211(3):286–289. doi: 10.1159/000087026.

75. Sam Saji A, Paudyal A, Audry De Souza V, Soman Pillai Radhamoney Amma S, Prajwalita Rai N. Primary palmar hyperhidrosis (PPH) accompanied with nevus flammeus: a case report. Cureus. 2023;15(5):e38723. doi: 10.7759/cureus.38723.

76. Stewart AG, Marsh F, Waterhouse JC, Howard P. Autonomic nerve dysfunction in COPD as assessed by the acetylcholine sweat-spot test. Eur Respir J. 1994;7(6):1090–1095. doi: 10.1183/09031936.94.07061090.

77. Singh S, Blanchard A, Walker JR, Graff LA, Miller N, Bernstein CN. Common symptoms and stressors among individuals with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2011;9(9):769–775. doi: 10.1016/j.cgh.2011.05.016.

78. Berdnikov A, McPhee S, LaBine L, Fatoye T. Night sweats as a manifestation of gastroesophageal reflux disease. Can Fam Physician. 2020;66(12):901–903. doi: 10.46747/cfp.6612901.

79. Murday HK, Rusli FD, Blandy C, Vollenhoven B. Night sweats: it may be hemochromatosis. Climacteric. 2016;19(4):406–408. doi: 10.1080/13697137.2016.1191461.

80. Drummond PD. Mechanisms of physiological gustatory sweating and flushing in the face. J Auton Nerv Syst. 1995;52(2–3):117–124. doi: 10.1016/0165-1838(94)00151-9.

81. Geraghty LN, Pomeranz MK. Physiologic changes and dermatoses of pregnancy. Int J Dermatol. 2011;50(7):771–782. doi: 10.1111/j.1365-4632.2010.04869.x.

82. Freedman RR. Menopausal hot flashes: mechanisms, endocrinology, treatment. J Steroid Biochem Mol Biol. 2014;142:115–120. doi: 10.1016/j.jsbmb.2013.08.010.

83. Crouch R, Akhras V, Sarkany R. Schnitzler’s syndrome: successful treatment with anakinra. Australas J Dermatol. 2007;48:178–181. doi: 10.1111/j.1440-0960.2007.00375.x.

84. Rzany B, Bechara FG, Feise K, Heckmann M, Rapprich S, Wörle B. Update of the S1 guidelines on the definition and treatment of primary hyperhidrosis. J Dtsch Dermatol Ges. 2018;16(8):945–952. doi: 10.1111/ddg.13579.

85. Fujimoto T. Pathophysiology and treatment of hyperhidrosis. Curr Probl Dermatol. 2016;51:86–93. doi: 10.1159/000446786.

86. Markantoni V, Tsiogka A, Agiasofitou E, et al. Clinical characteristics and treatment options for multifocal hyperhidrosis in a single-center real-world population. J Eur Acad Dermatol Venereol. 2023;37:e1310–e1313. doi: 10.1111/jdv.19303.

87. Naumann MK, Hamm H, Lowe NJ Botox Hyperhidrosis Clinical Study Group. Effect of botulinum toxin type A on quality of life measures in patients with excessive axillary sweating: a randomized controlled trial. Br J Dermatol. 2002;147(6):1218–1226. doi: 10.1046/j.1365-2133.2002.05059.x.

88. Guillet MH, Wierzbicka E, Guillet S, Dagregorio G, Guillet G. A 3-year causative study of pompholyx in 120 patients. Arch Dermatol. 2007;143(12):1504–1508. doi: 10.1001/archderm.143.12.1504.

89. Leung AK, Chan PY, Choi MC. Hyperhidrosis. Int J Dermatol. 1999;38(8):561–567. doi: 10.1046/j.1365-4362.1999.00609.x.

90. He J, Wang T, Dong J. A close positive correlation between malodor and sweating as a marker for the treatment of axillary bromhidrosis with botulinum toxin A. J Dermatolog Treat. 2012;23(6):461–464. doi: 10.3109/09546634.2011.594869.

91. Farrugia MK, Nicholls EA. Intradermal botulinum A toxin injection for axillary hyperhydrosis. J Pediatr Surg. 2005;40(10):1668–1669. doi: 10.1016/j.jpedsurg.2005.06.023.

92. Cohen JL, Cohen G, Solish N, Murray CA. Diagnosis, impact, and management of focal hyperhidrosis: treatment review including botulinum toxin therapy. Facial Plast Surg Clin North Am. 2007;15(1):17–30. doi: 10.1016/j.fsc.2006.10.002.

93. Solish N, Wang R, Murray CA. Evaluating the patient presenting with hyperhidrosis. Thorac Surg Clin. 2008;18(2):133–140. doi: 10.1016/j.thorsurg.2008.01.002.

94. Hornberger J, Grimes K, Naumann M, et al. Recognition, diagnosis, and treatment of primary focal hyperhidrosis. J Am Acad Dermatol. 2004;51(2):274–286. doi: 10.1016/j.jaad.2003.12.029.

95. Glaser DA, Hebert AA, Pariser DM, Solish N. Primary focal hyperhidrosis: scope of the problem. Cutis. 2007;79(Suppl 5):5–17.

96. Vary JC., Jr Selected disorders of skin appendages – acne, alopecia, hyperhidrosis. Med Clin North Am. 2015;99(6):1195–1211. doi: 10.1016/j.mcna.2015.07.003.

97. Johnson C, Smereck J. Unilateral mydriasis due to a topical “anti-sweat” preparation. J Emerg Med. 2013;44:673–674. doi: 10.1016/j.jemermed.2012.09.021.

98. Campanati A, Penna L, Guzzo T, et al. Quality-of-life assessment in patients with hyperhidrosis before and after treatment with botulinum toxin: results of an open-label study. Clin Ther. 2003;25(1):298–308. doi: 10.1016/s0149-2918(03)90041-5.

99. Hund M, Kinkelin I, Naumann M, Hamm H. Definition of axillary hyperhidrosis by gravimetric assessment. Arch Dermatol. 2002;138(4):539–541. doi: 10.1001/archderm.138.4.539.

100. Heckmann M, Ceballos-Baumann AO, Plewig G Hyperhidrosis Study Group. Botulinum toxin A for axillary hyperhidrosis (excessive sweating) N Engl J Med. 2001;344(7):488–493. doi: 10.1056/NEJM200102153440704.

101. Low PA, Caskey PE, Tuck RR, Fealey RD, Dyck PJ. Quantitative sudomotor axon reflex test in normal and neuropathic subjects. Ann Neurol. 1983;14(5):573–580. doi: 10.1002/ana.410140513.

102. Lang E, Foerster A, Pfannmüller D, Handwerker HO. Quantitative assessment of sudomotor activity by capacitance hygrometry. Clin Auton Res. 1993;3(2):107–115. doi: 10.1007/BF01818995.

103. Kihara M, Opfer-Gehrking TL, Low PA. Comparison of directly stimulated with axon-reflex-mediated sudomotor responses in human subjects and in patients with diabetes. Muscle Nerve. 1993;16(6):655–660. doi: 10.1002/mus.880160612.

104. Cetindag IB, Boley TM, Webb KN, Hazelrigg SR. Long-term results and quality-of-life measures in the management of hyperhidrosis. Thorac Surg Clin. 2008;18(2):217–222. doi: 10.1016/j.thorsurg.2008.01.009.

105. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) – a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–216. doi: 10.1111/j.1365-2230.1994.tb01167.x.

106. Basra MK, Fenech R, Gatt RM, Salek MS, Finlay AY. The Dermatology Life Quality Index 1994–2007: a comprehensive review of validation data and clinical results. Br J Dermatol. 2008;159(5):997–1035. doi: 10.1111/j.1365-2133.2008.08832.x.

107. Swan MC, Paes T. Quality of life evaluation following endoscopic transthoracic sympathectomy for upper limb and facial hyperhidrosis. Ann Chir Gynaecol. 2001;90(3):157–159.

108. Ware J, Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34(3):220–233. doi: 10.1097/00005650-199603000-00003.

109. Lenefsky M, Rice ZP. Hyperhidrosis and its impact on those living with it. Am J Manag Care. 2018;24(Suppl 23):S491–S495.

110. Hasimoto EN, Cataneo DC, Reis TAD, Cataneo AJM. Hyperhidrosis: prevalence and impact on quality of life. J Bras Pneumol. 2018;44(4):292–298. doi: 10.1590/S1806-37562017000000379.

111. Kjeldstrup Kristensen J, Grejsen D, Swartling C, Bygum A. In hyperhidrosis quality of life is even worse than in acne, eczema, or psoriasis: a comparison of Skindex-16 and Dermatology Life Quality Index (DLQI) Int J Dermatol. 2020;59(11):e392–e393. doi: 10.1111/ijd.15164.

112. Kristensen JK, Nielsen C. Decreased work productivity due to primary palmar hyperhidrosis. What is the cost? Skin Health Dis. 2021;1(2):e24. doi: 10.1002/ski2.24.

113. Kamudoni P, Mueller B, Halford J, Schouveller A, Stacey B, Salek MS. The impact of hyperhidrosis on patients’ daily life and quality of life: a qualitative investigation. Health Qual Life Outcomes. 2017;15(1):121. doi: 10.1186/s12955-017-0693-x.

114. Nawrocki S, Cha J. The etiology, diagnosis, and management of hyperhidrosis: a comprehensive review: therapeutic options. J Am Acad Dermatol. 2019;81(3):669–680. doi: 10.1016/j.jaad.2018.11.066.

115. Remington C, Ruth J, Hebert AA. Primary hyperhidrosis in children: a review of therapeutics. Pediatr Dermatol. 2021;38(3):561–567. doi: 10.1111/pde.14551.

116. Campanati A, Gregoriou S, Milia-Argyti A, et al. The pharmacological treatment and management of hyperhidrosis. Expert Opin Pharmacother. 2022;23(10):1217–1231. doi: 10.1080/14656566.2022.2083499.

117. Hoverson K, Kandula P. Hyperhidrosis: a review and treatment options. Adv Cosmet Surg. 2020;3(1):155–163. doi: 10.1016/j.yacs.2020.01.014.

118. Morgado-Carrasco D, de Lucas R. [Translated article] Topical anticholinergics in the management of focal hyperhidrosis in adults and children. A narrative review. Actas Dermosifiliogr. 2024;115(4):T356–T367. doi: 10.1016/j.ad.2023.09.025.

119. Henning MAS, Bouazzi D, Jemec GBE. Treatment of hyperhidrosis: an update. Am J Clin Dermatol. 2022;23:635–646. doi: 10.1007/s40257-022-00707-x.

120. Scholes KT, Crow KD, Ellis JP, Harman RR, Saihan EM. Axillary hyperhidrosis treated with alcoholic solution of aluminium chloride hexahydrate. Br Med J. 1978;2(6130):84–85. doi: 10.1136/bmj.2.6130.84.

121. Gee S, Yamauchi PS. Nonsurgical management of hyperhidrosis. Thorac Surg Clin. 2008;18(2):141–155. doi: 10.1016/j.thorsurg.2008.01.003.

122. Glaser DA, Hebert AA, Nast A, et al. Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials. J Am Acad Dermatol. 2019;80(1):128–138e2. doi: 10.1016/j.jaad.2018.07.002.

123. Pariser DM, Hebert AA, Drew J, Quiring J, Gopalan R, Glaser DA. Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: patient-reported outcomes from the ATMOS-1 and ATMOS-2 phase III randomized controlled trials. Am J Clin Dermatol. 2019;20(1):135–145. doi: 10.1007/s40257-018-0395-0.

124. Gregoriou S, Markantoni V, Campanati A, et al. Treatment of axillary bromhidrosis with topical 2% glycopyrronium bromide cream: a prospective, non-randomized, open-label study. J Clin Aesthet Dermatol. 2021;14(11):E61–E63.

125. Yokozeki H, Fujimoto T, Wanatabe S, Ogawa S, Fujii C. Topical glycopyrronium tosylate in Japanese patients with primary axillary hyperhidrosis: a randomized, double-blind, vehicle-controlled study. J Dermatol. 2022;49(1):86–94. doi: 10.1111/1346-8138.16188.

126. Hyun MY, Son IP, Lee Y, et al. Efficacy and safety of topical glycopyrrolate in patients with facial hyperhidrosis: a randomized, multicentre, double-blinded, placebo-controlled, split-face study. J Eur Acad Dermatol Venereol. 2015;29(2):278–282. doi: 10.1111/jdv.12518.

127. Kim WO, Kil HK, Yoon KB, Yoon DM. Topical glycopyrrolate for patients with facial hyperhidrosis. Br J Dermatol. 2008;158(5):1094–1097. doi: 10.1111/j.1365-2133.2008.08476.x.

128. Nofal E, Salem S, Khashaba SA. Intradermal botulinum toxin A injection versus topical 2% glycopyrrolate for the treatment of primary facial hyperhidrosis: a pilot study and review of literature. Dermatol Surg. 2022;48(8):843–848. doi: 10.1097/DSS.0000000000003490.

129. Hebert AA, Glaser DA, Green L, et al. Long-term efficacy and safety of topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: post hoc pediatric subgroup analysis from a 44-week open-label extension study. Pediatr Dermatol. 2020;37(3):490–497. doi: 10.1111/pde.14135.

130. Artzi O, Loizides C, Zur E, Sprecher E. Topical oxybutynin 10% gel for the treatment of primary focal hyperhidrosis: a randomized double-blind placebo-controlled split area study. Acta Derm Venereol. 2017;97(9):1120–1124. doi: 10.2340/00015555-2731.

131. Saki N, Shakouri N, Rastaghi F, Hosseini SA, Alipour S, Ahramiyanpour N. Oxybutynin gel versus nanoemulgel for treating primary palmar hyperhidrosis: a pilot double-blind randomized controlled trial. J Cosmet Dermatol. 2023;22(8):2268–2272. doi: 10.1111/jocd.15715.

132. Fujimoto T, Terahara T, Okawa K, Inakura H, Hirayama Y, Yokozeki H. A novel lotion formulation of 20% oxybutynin hydrochloride for the treatment of primary palmar hyperhidrosis: a randomized, placebo-controlled, double-blind, phase III study. J Am Acad Dermatol. 2023;89(1):62–69. doi: 10.1016/j.jaad.2023.03.025.

133. Nguyen NV, Gralla J, Abbott J, Bruckner AL. Oxybutynin 3% gel for the treatment of primary focal hyperhidrosis in adolescents and young adults. Pediatr Dermatol. 2018;35(2):208–212. doi: 10.1111/pde.13404.

134. Kirsch B, Smith S, Cohen J, et al. Efficacy and safety of topical sofpironium bromide gel for the treatment of axillary hyperhidrosis: a phase II, randomized, controlled, double-blinded trial. J Am Acad Dermatol. 2020;82(6):1321–1327. doi: 10.1016/j.jaad.2020.02.016.

135. Fujimoto T, Abe Y, Igarashi M, et al. A phase III, 52-week, open-label study to evaluate the safety and efficacy of 5% sofpironium bromide (BBI-4000) gel in Japanese patients with primary axillary hyperhidrosis. J Dermatol. 2021;48(8):1149–1161. doi: 10.1111/1346-8138.15927.

136. Yokozeki H, Fujimoto T, Abe Y, et al. A phase 3, multicenter, randomized, double-blind, vehicle-controlled, parallel-group study of 5% sofpironium bromide (BBI-4000) gel in Japanese patients with primary axillary hyperhidrosis. J Dermatol. 2021;48(3):279–288. doi: 10.1111/1346-8138.15668.

137. Nasir A, Bissonnette R, Maari C, et al. A phase 2a randomized controlled study to evaluate the pharmacokinetic, safety, tolerability and clinical effect of topically applied Umeclidinium in subjects with primary axillary hyperhidrosis. J Eur Acad Dermatol Venereol. 2018;32(1):145–151. doi: 10.1111/jdv.14651.

138. Glaser DA. Oral medications. Dermatol Clin. 2014;32(4):527–532. doi: 10.1016/j.det.2014.06.002.

139. Bajaj V, Langtry JA. Use of oral glycopyrronium bromide in hyperhidrosis. Br J Dermatol. 2007;157(1):118–121. doi: 10.1111/j.1365-2133.2007.07884.x.

140. Cruddas L, Baker DM. Treatment of primary hyperhidrosis with oral anticholinergic medications: a systematic review. J Eur Acad Dermatol Venereol. 2017;31(6):952–963. doi: 10.1111/jdv.14081.

141. Wolosker N, de Campos JR, Kauffman P, Puech-Leão P. A randomized placebo-controlled trial of oxybutynin for the initial treatment of palmar and axillary hyperhidrosis. J Vasc Surg. 2012;55(6):1696–1700. doi: 10.1016/j.jvs.2011.12.039.

142. Schollhammer M, Brenaut E, Menard-Andivot N, et al. Oxybutynin as a treatment for generalized hyperhidrosis: a randomized, placebo-controlled trial. Br J Dermatol. 2015;173(5):1163–1168. doi: 10.1111/bjd.13973.

143. Wolosker N, Teivelis MP, Krutman M, et al. Long-term efficacy of oxybutynin for palmar and plantar hyperhidrosis in children younger than 14 years. Pediatr Dermatol. 2015;32(5):663–667. doi: 10.1111/pde.12385.

144. Müller C, Berensmeier A, Hamm H, et al. Efficacy and safety of methantheline bromide (Vagantin®) in axillary and palmar hyperhidrosis: results from a multicenter, randomized, placebo-controlled trial. J Eur Acad Dermatol Venereol. 2013;27(10):1278–1284. doi: 10.1111/j.1468-3083.2012.04708.x.

145. Walling HW. Systemic therapy for primary hyperhidrosis: a retrospective study of 59 patients treated with glycopyrrolate or clonidine. J Am Acad Dermatol. 2012;66(3):387–392. doi: 10.1016/j.jaad.2011.01.023.

146. Solish N, Bertucci V, Dansereau A, et al. A comprehensive approach to the recognition, diagnosis, and severity-based treatment of focal hyperhidrosis: recommendations of the Canadian Hyperhidrosis Advisory Committee. Dermatol Surg. 2007;33(8):908–923. doi: 10.1111/j.1524-4725.2007.33192.x.

147. Dagash H, McCaffrey S, Mellor K, Roycroft A, Helbling I. Tap water iontophoresis in the treatment of pediatric hyperhidrosis. J Pediatr Surg. 2017;52(2):309–312. doi: 10.1016/j.jpedsurg.2016.11.026.

148. Wörle B, Rapprich S, Heckmann M. Definition and treatment of primary hyperhidrosis. J Dtsch Dermatol Ges. 2007;5(7):625–628. doi: 10.1111/j.1610-0387.2007.06409.x.

149. Hoorens I, Ongenae K. Primary focal hyperhidrosis: current treatment options and a step-by-step approach. J Eur Acad Dermatol Venereol. 2012;26(1):1–8. doi: 10.1111/j.1468-3083.2011.04173.x.

150. Özcan D, Güleç AT. Compliance with tap water iontophoresis in patients with palmoplantar hyperhidrosis. J Cutan Med Surg. 2014;18(2):109–113. doi: 10.2310/7750.2013.13105.

151. Karakoç Y, Aydemir EH, Kalkan MT, Unal G. Safe control of palmoplantar hyperhidrosis with direct electrical current. Int J Dermatol. 2002;41(9):602–605. doi: 10.1046/j.1365-4362.2002.01473.x.

152. Hong HC, Lupin M, O’Shaughnessy KF. Clinical evaluation of a microwave device for treating axillary hyperhidrosis. Dermatol Surg. 2012;38(5):728–735. doi: 10.1111/j.1524-4725.2012.02375.x.

153. Glaser DA, Coleman WP, 3rd, Fan LK, et al. A randomized, blinded clinical evaluation of a novel microwave device for treating axillary hyperhidrosis: the dermatologic reduction in underarm perspiration study. Dermatol Surg. 2012;38(2):185–191. doi: 10.1111/j.1524-4725.2011.02250.x.

154. Commons GW, Lim AF. Treatment of axillary hyperhidrosis/bromidrosis using VASER ultrasound. Aesth Plast Surg. 2009;33(3):312–323. doi: 10.1007/s00266-008-9283-y.

155. Glaser DA, Galperin TA. Managing hyperhidrosis: emerging therapies. Dermatol Clin. 2014;32(4):549–553. doi: 10.1016/j.det.2014.06.003.

156. Nestor MS, Park H. Safety and efficacy of micro-focused ultrasound plus visualization for the treatment of axillary hyperhidrosis. J Clin Aesthet Dermatol. 2014;7(4):14–21.

157. Macedo O, Matayoshi L, Matsumoto L. The new ultrasound technology for hyperhidrosis treatment: two case reports. J Am Acad Dermatol. 2013;68(4):AB66. doi: 10.1016/j.jaad.2012.12.273.

158. Schick CH, Grallath T, Schick KS, Hashmonai M. Radiofrequency thermotherapy for treating axillary hyperhidrosis. Dermatol Surg. 2016;42(5):624–630. doi: 10.1097/DSS.0000000000000703.

159. Kim M, Shin JY, Lee J, Kim JY, Oh SH. Efficacy of fractional microneedle radiofrequency device in the treatment of primary axillary hyperhidrosis: a pilot study. Dermatology. 2013;227(3):243–249. doi: 10.1159/000354602.

160. Fatemi Naeini F, Abtahi-Naeini B, Pourazizi M, Nilforoushzadeh MA, Mirmohammadkhani M. Fractionated microneedle radiofrequency for treatment of primary axillary hyperhidrosis: a sham control study. Australas J Dermatol. 2015;56(4):279–284. doi: 10.1111/ajd.12260.

161. Rummaneethorn P, Chalermchai T. A comparative study between intradermal botulinum toxin A and fractional microneedle radiofrequency (FMR) for the treatment of primary axillary hyperhidrosis. Lasers Med Sci. 2020;35(5):1179–1184. doi: 10.1007/s10103-020-02958-8.

162. Aydin F, Pancar GS, Senturk N, et al. Axillary hair removal with 1064-nm Nd:YAG laser increases sweat production. Clin Exp Dermatol. 2010;35(6):588–592. doi: 10.1111/j.1365-2230.2009.03638.x.

163. Obeid G, Helou J, Maatouk I, Moutran R, Tomb R. Depilatory laser: a potential causative factor for inguinal hyperhidrosis: report of three cases. J Cosmet Laser Ther. 2013;15(5):286–289. doi: 10.3109/14764172.2012.761344.

164. Bechara FG, Georgas D, Sand M, et al. Effects of a long-pulsed 800-nm diode laser on axillary hyperhidrosis: a randomized controlled half-side comparison study. Dermatol Surg. 2012;38(5):736–740. doi: 10.1111/j.1524-4725.2012.02339.x.

165. Leclère FM, Moreno-Moraga J, Alcolea JM, et al. Efficacy and safety of laser therapy on axillary hyperhidrosis after one year follow-up: a randomized blinded controlled trial. Lasers Surg Med. 2015;47(2):173–179. doi: 10.1002/lsm.22324.

166. Letada PR, Landers JT, Uebelhoer NS, Shumaker PR. Treatment of focal axillary hyperhidrosis using a long-pulsed Nd:YAG 1064 nm laser at hair reduction settings. J Drugs Dermatol. 2012;11(1):59–63.

167. Naumann M, Lowe NJ. Botulinum toxin type A in treatment of bilateral primary axillary hyperhidrosis: randomised, parallel group, double blind, placebo controlled trial. BMJ. 2001;323(7313):596–599. doi: 10.1136/bmj.323.7313.596.

168. Heckmann M, Plewig G Hyperhidrosis Study Group. Low-dose efficacy of botulinum toxin A for axillary hyperhidrosis: a randomized, side-by-side, open-label study. Arch Dermatol. 2005;141(10):1255–1259. doi: 10.1001/archderm.141.10.1255.

169. de Almeida AR, Montagner S. Botulinum toxin for axillary hyperhidrosis. Dermatol Clin. 2014;32(4):495–504. doi: 10.1016/j.det.2014.06.013.

170. Glaser DA, Pariser DM, Hebert AA, et al. A prospective, nonrandomized, open-label study of the efficacy and safety of onabotulinumtoxinA in adolescents with primary axillary hyperhidrosis. Pediatr Dermatol. 2015;32(5):609–617. doi: 10.1111/pde.12620.

171. George SM, Atkinson LR, Farrant PB, Shergill BS. Botulinum toxin for focal hyperhidrosis of the face. Br J Dermatol. 2014;170(1):211–213. doi: 10.1111/bjd.12568.

172. Böger A, Herath H, Rompel R, Ferbert A. Botulinum toxin for treatment of craniofacial hyperhidrosis. J Neurol. 2000;247(11):857–861. doi: 10.1007/s004150070073.

173. Glaser DA, Hebert AA, Pariser DM, Solish N. Facial hyperhidrosis: best practice recommendations and special considerations. Cutis. 2007;79(Suppl 5):29–32.

174. Walling HW, Swick BL. Treatment options for hyperhidrosis. Am J Clin Dermatol. 2011;12(5):285–295. doi: 10.2165/11587870-000000000-00000.

175. Wollina U, Köstler E, Schönlebe J, Haroske G. Tumescent suction curettage versus minimal skin resection with subcutaneous curettage of sweat glands in axillary hyperhidrosis. Dermatol Surg. 2008;34(5):709–716. doi: 10.1111/j.1524-4725.2008.34132.x.

176. Bechara FG, Sand M, Hoffmann K, Boorboor P, Altmeyer P, Stuecker M. Histological and clinical findings in different surgical strategies for focal axillary hyperhidrosis. Dermatol Surg. 2008;34(8):1001–1009. doi: 10.1111/j.1524-4725.2008.34198.x.

177. Bechara FG, Gambichler T, Bader A, Sand M, Altmeyer P, Hoffmann K. Assessment of quality of life in patients with primary axillary hyperhidrosis before and after suction-curettage. J Am Acad Dermatol. 2007;57(2):207–212. doi: 10.1016/j.jaad.2007.01.035.

178. Darabaneanu S, Darabaneanu HA, Niederberger U, Russo PA, Lischner S, Hauschild A. Long-term efficacy of subcutaneous sweat gland suction curettage for axillary hyperhidrosis: a prospective gravimetrically controlled study. Dermatol Surg. 2008;34(9):1170–1177. doi: 10.1111/j.1524-4725.2008.34255.x.

179. Ibrahim O, Kakar R, Bolotin D, et al. The comparative effectiveness of suction-curettage and onabotulinumtoxin-A injections for the treatment of primary focal axillary hyperhidrosis: a randomized control trial. J Am Acad Dermatol. 2013;69(1):88–95. doi: 10.1016/j.jaad.2013.02.013.

180. Coleman WP., 3rd Liposuction for axillary hyperhidrosis. J Am Acad Dermatol. 2013;69(6):1062. doi: 10.1016/j.jaad.2013.08.009.

181. Lee MR, Ryman WJ. Liposuction for axillary hyperhidrosis. Australas J Dermatol. 2005;46(2):76–79. doi: 10.1111/j.1440-0960.2005.00145.x.

182. Feldmeyer L, Bogdan I, Moser A, et al. Short- and long-term efficacy and mechanism of action of tumescent suction curettage for axillary hyperhidrosis. J Eur Acad Dermatol Venereol. 2015;29(10):1933–1937. doi: 10.1111/jdv.13078.

183. Field LM. Re: Insufficient aggressiveness with tumescent suction curettage. Dermatol Surg. 2009;35(3):555–556. doi: 10.1111/j.1524-4725.2009.01084.x.

184. Connolly M, de Berker D. Management of primary hyperhidrosis: a summary of the different treatment modalities. Am J Clin Dermatol. 2003;4(10):681–697. doi: 10.2165/00128071-200304100-00003.

185. Moraites E, Vaughn OA, Hill S. Endoscopic thoracic sympathectomy. Dermatol Clin. 2014;32(4):541–548. doi: 10.1016/j.det.2014.06.007.

186. Mol A, Muensterer OJ. Over a decade of single-center experience with thoracoscopic sympathicolysis for primary palmar hyperhidrosis: a case series. Surg Endosc. 2021;35(7):3313–3319. doi: 10.1007/s00464-020-07769-0.

187. Cerfolio RJ, De Campos JR, Bryant AS, et al. The Society of Thoracic Surgeons expert consensus for the surgical treatment of hyperhidrosis. Ann Thorac Surg. 2011;91(5):1642–1648. doi: 10.1016/j.athoracsur.2011.01.105.

188. Lin TS, Fang HY. Transthoracic endoscopic sympathectomy in the treatment of palmar hyperhidrosis--with emphasis on perioperative management (1,360 case analyses) Surg Neurol. 1999;52(5):453–457. doi: 10.1016/s0090-3019(99)00111-1.

189. Doolabh N, Horswell S, Williams M, et al. Thoracoscopic sympathectomy for hyperhidrosis: indications and results. Ann Thorac Surg. 2004;77(2):410–414. doi: 10.1016/j.athoracsur.2003.06.003.

190. Herbst F, Plas EG, Függer R, Fritsch A. Endoscopic thoracic sympathectomy for primary hyperhidrosis of the upper limbs. A critical analysis and long-term results of 480 operations. Ann Surg. 1994;220(1):86–90. doi: 10.1097/00000658-199407000-00012.

191. Singh S, Kaur S, Wilson P. Plantar hyperhidrosis: a review of current management. J Dermatolog Treat. 2016;27(6):556–561. doi: 10.3109/09546634.2016.1163319.

192. de Andrade Filho LO, Kuzniec S, Wolosker N, Yazbek G, Kauffman P, Milanez de Campos JR. Technical difficulties and complications of sympathectomy in the treatment of hyperhidrosis: an analysis of 1731 cases. Ann Vasc Surg. 2013;27(4):447–453. doi: 10.1016/j.avsg.2012.05.026.

193. Cinà CS, Cinà MM, Clase CM. Endoscopic thoracic sympathectomy for hyperhidrosis: technique and results. J Minim Access Surg. 2007;3(4):132–140. doi: 10.4103/0972-9941.38907.

194. Shih CJ, Wu JJ, Lin MT. Autonomic dysfunction in palmar hyperhidrosis. J Auton Nerv Syst. 1983;8(1):33–43. doi: 10.1016/0165-1838(83)90021-8.

195. Gorenstein LA, Krasna MJ. Less common side effects of sympathetic surgery. Thorac Surg Clin. 2016;26(4):453–458. doi: 10.1016/j.thorsurg.2016.06.010.

196. Hashmonai M. The history of sympathetic surgery. Thorac Surg Clin. 2016;26(4):383–388. doi: 10.1016/j.thorsurg.2016.06.001.

197. de Menezes Lyra R, Campos JR, Kang DW, et al. Guidelines for the prevention, diagnosis and treatment of compensatory hyperhidrosis. J Bras Pneumol. 2008;34(11):967–977. doi: 10.1590/s1806-37132008001100013.

198. de Campos JR, Kauffman P, de Werebe EC, et al. Quality of life, before and after thoracic sympathectomy: report on 378 operated patients. Ann Thorac Surg. 2003;76(3):886–891. doi: 10.1016/s0003-4975(03)00895-6.

199. Atkinson JL, Fealey RD. Sympathotomy instead of sympathectomy for palmar hyperhidrosis: minimizing postoperative compensatory hyperhidrosis. Mayo Clin Proc. 2003;78(2):167–172. doi: 10.4065/78.2.167.

200. Amini M, Harmsze AM, Tupker RA. Patient’s estimation of efficacy of various hyperhidrosis treatments in a dermatological clinic. Acta Derm Venereol. 2008;88(4):356–362. doi: 10.2340/00015555-0440.

201. Vlahovic TC. Plantar hyperhidrosis: an overview. Clin Podiatr Med Surg. 2016;33(3):441–451. doi: 10.1016/j.cpm.2016.02.010.

202. Pariser DM, Ballard A. Topical therapies in hyperhidrosis care. Dermatol Clin. 2014;32(4):485–490. doi: 10.1016/j.det.2014.06.008.

203. Hölzle E, Braun-Falco O. Structural changes in axillary eccrine glands following long-term treatment with aluminium chloride hexahydrate solution. Br J Dermatol. 1984;110(4):399–403. doi: 10.1111/j.1365-2133.1984.tb04653.x.

204. Hölzle E. Topical pharmacological treatment. Curr Probl Dermatol. 2002;30:30–43. doi: 10.1159/000060693.

205. White JW., Jr Treatment of primary hyperhidrosis. Mayo Clin Proc. 1986;61(12):951–956. doi: 10.1016/s0025-6196(12)62635-4.

206. Flanagan KH, Glaser DA. An open-label trial of the efficacy of 15% aluminum chloride in 2% salicylic acid gel base in the treatment of moderate-to-severe primary axillary hyperhidrosis. J Drugs Dermatol. 2009;8(5):477–480.

207. Glent-Madsen L, Dahl JC. Axillary hyperhidrosis. Local treatment with aluminium-chloride hexahydrate 25% in absolute ethanol with and without supplementary treatment with triethanolamine. Acta Derm Venereol. 1988;68(1):87–89.

208. Benohanian A, Dansereau A, Bolduc C, Bloom E. Localized hyperhidrosis treated with aluminum chloride in a salicylic acid gel base. Int J Dermatol. 1998;37(9):701–703. doi: 10.1046/j.1365-4362.1998.00543.x.

209. Pariser D, Rivera E, Benedict D. Open-label cohort study to evaluate efficacy and safety of application of glycopyrronium cloth, 2.4% for palmar hyperhidrosis. J Drugs Dermatol. 2022;21(5):488–495. doi: 10.36849/JDD.6688.

210. Glaser DA, Hebert AA, Nast A, et al. A 44-week open-label study evaluating safety and efficacy of topical glycopyrronium tosylate in patients with primary axillary hyperhidrosis. Am J Clin Dermatol. 2019;20(4):593–604. doi: 10.1007/s40257-019-00446-6.

211. Lueangarun S, Sermsilp C, Tempark T. Topical botulinum toxin type A liposomal cream for primary axillary hyperhidrosis: a double-blind, randomized, split-site, vehicle-controlled study. Dermatol Surg. 2018;44(8):1094–1101. doi: 10.1097/DSS.0000000000001532.

212. Lakraj AA, Moghimi N, Jabbari B. Hyperhidrosis: anatomy, pathophysiology and treatment with emphasis on the role of botulinum toxins. Toxins. 2013;5(4):821–840. doi: 10.3390/toxins5040821.

213. Hamm H, Naumann MK, Kowalski JW, Kütt S, Kozma C, Teale C. Primary focal hyperhidrosis: disease characteristics and functional impairment. Dermatology. 2006;212(4):343–353. doi: 10.1159/000092285.

214. Dolianitis C, Scarff CE, Kelly J, Sinclair R. Iontophoresis with glycopyrrolate for the treatment of palmoplantar hyperhidrosis. Australas J Dermatol. 2004;45(4):208–212. doi: 10.1111/j.1440-0960.2004.00098.x.

215. Chia HY, Tan AS, Chong WS, Tey HL. Efficacy of iontophoresis with glycopyrronium bromide for treatment of primary palmar hyperhidrosis. J Eur Acad Dermatol Venereol. 2012;26(9):1167–1170. doi: 10.1111/j.1468-3083.2011.04197.x.

216. Gujjar M, Banga AK. Iontophoretic and microneedle mediated transdermal delivery of glycopyrrolate. Pharmaceutics. 2014;6(4):663–671. doi: 10.3390/pharmaceutics6040663.

217. Abell E, Morgan K. The treatment of idiopathic hyperhidrosis by glycopyrronium bromide and tap water iontophoresis. Br J Dermatol. 1974;91(1):87–91. doi: 10.1111/j.1365-2133.1974.tb06722.x.

218. Davarian S, Kalantari KK, Rezasoltani A, Rahimi A. Effect and persistency of botulinum toxin iontophoresis in the treatment of palmar hyperhidrosis. Australas J Dermatol. 2008;49(2):75–79. doi: 10.1111/j.1440-0960.2008.00441.x.

219. Khademi Kalantari K, Zeinalzade A, Kobarfard F, Nazary Moghadam S. The effect and persistency of 1% aluminum chloride hexahydrate iontophoresis in the treatment of primary palmar hyperhidrosis. Iran J Pharm Res. 2011;10(3):641–645. doi: 10.22037/ijpr.2011.995.

220. Atkins JL, Butler PE. Hyperhidrosis: a review of current management. Plast Reconstr Surg. 2002;110(1):222–228. doi: 10.1097/00006534-200207000-00039.

221. Ram R, Lowe NJ, Yamauchi PS. Current and emerging therapeutic modalities for hyperhidrosis, part 1: conservative and noninvasive treatments. Cutis. 2007;79(3):211–217.

222. Choi YH, Lee SJ, Kim DW, Lee WJ, Na GY. Open clinical trial for evaluation of efficacy and safety of a portable “dry-type” iontophoretic device in treatment of palmar hyperhidrosis. Dermatol Surg. 2013;39(4):578–583. doi: 10.1111/dsu.12099.

223. Pariser DM, Ballard A. Iontophoresis for palmar and plantar hyperhidrosis. Dermatol Clin. 2014;32(4):491–494. doi: 10.1016/j.det.2014.06.009.

224. Sánchez-Carpintero I, Martín-Gorgojo A, Ruiz-Rodríguez R. Microwave treatment for axillary hyperhidrosis and bromhidrosis. Tratamiento con microondas en la hiperhidrosis y bromhidrosis axilar. Actas Dermosifiliogr. 2017;108(5):418–422. doi: 10.1016/j.ad.2016.12.011.

225. Grabell DA, Hebert AA. Current and emerging medical therapies for primary hyperhidrosis. Dermatol Ther. 2017;7(1):25–36. doi: 10.1007/s13555-016-0148-z.

226. Leow MQH, Tey HL. Treatment of primary palmar hyperhidrosis using glycopyrrolate iontophoresis: intensity of electrical current used, efficacy and side effects. Indian J Dermatol Venereol Leprol. 2017;83(3):387–388. doi: 10.4103/0378-6323.201338.

227. Kaminaka C, Mikita N, Inaba Y, et al. Clinical and histological evaluation of a single high energy microwave treatment for primary axillary hyperhidrosis in Asians: a prospective, randomized, controlled, split-area comparative trial. Lasers Surg Med. 2019;51(7):592–599. doi: 10.1002/lsm.23073.

228. Suh DH, Lee SJ, Kim K, Ryu HJ. Transient median and ulnar neuropathy associated with a microwave device for treating axillary hyperhidrosis. Dermatol Surg. 2014;40(4):482–485. doi: 10.1111/dsu.12425.

229. Chang CK, Chen CY, Hsu KF, et al. Brachial plexus injury after microwave-based treatment for axillary hyperhidrosis and osmidrosis. J Cosmet Laser Ther. 2017;19(7):439–441. doi: 10.1080/14764172.2017.1342039.

230. Weinberg T, Solish N, Murray C. Botulinum neurotoxin treatment of palmar and plantar hyperhidrosis. Dermatol Clin. 2014;32(4):505–515. doi: 10.1016/j.det.2014.06.012.

231. Yamauchi PS, Lowe NJ. Botulinum toxin types A and B: comparison of efficacy, duration, and dose-ranging studies for the treatment of facial rhytides and hyperhidrosis. Clin Dermatol. 2004;22(1):34–39. doi: 10.1016/j.clindermatol.2003.11.005.

232. Baumann L, Slezinger A, Halem M, et al. Pilot study of the safety and efficacy of Myobloc (botulinum toxin type B) for treatment of axillary hyperhidrosis. Int J Dermatol. 2005;44(5):418–424. doi: 10.1111/j.1365-4632.2004.02531.x.

233. Baumann LS, Halem ML. Botulinum toxin-B and the management of hyperhidrosis. Clin Dermatol. 2004;22(1):60–65. doi: 10.1016/j.clindermatol.2003.11.001.

234. Benohanian A. Needle-free anaesthesia prior to botulinum toxin type A injection treatment of palmar and plantar hyperhidrosis. Br J Dermatol. 2007;156(3):593–596. doi: 10.1111/j.1365-2133.2007.07691.x.

235. Smith KC, Comite SL, Storwick GS. Ice minimizes discomfort associated with injection of botulinum toxin type A for the treatment of palmar and plantar hyperhidrosis. Dermatol Surg. 2007;33(1 Spec No):S88–S91. doi: 10.1111/j.1524-4725.2006.32337.x.

236. Moraru E, Auff E, Schnider P. Hyperhidrosis of the palms and soles. Curr Probl Dermatol. 2002;30:156–169. doi: 10.1159/000060689.

237. Torrisi BM, Zarnitsyn V, Prausnitz MR, et al. Pocketed microneedles for rapid delivery of a liquid-state botulinum toxin A formulation into human skin. J Control Release. 2013;165(2):146–152. doi: 10.1016/j.jconrel.2012.11.010.

238. O’Riordan JM, Fitzgerald E, Gowing C, O’Grady H, Feeley TM, Tierney S. Topical local anaesthetic (tetracaine) reduces pain from botulinum toxin injections for axillary hyperhidrosis. Br J Surg. 2006;93(6):713–714. doi: 10.1002/bjs.5347.

239. Elibol O, Ozkan B, Hekimhan PK, Cağlar Y. Efficacy of skin cooling and EMLA cream application for pain relief of periocular botulinum toxin injection. Ophthalmic Plast Reconstr Surg. 2007;23(2):130–133. doi: 10.1097/IOP.0b013e318030459c.

240. Güleç AT. Dilution of botulinum toxin A in lidocaine vs. in normal saline for the treatment of primary axillary hyperhidrosis: a double-blind, randomized, comparative preliminary study. J Eur Acad Dermatol Venereol. 2012;26(3):314–318. doi: 10.1111/j.1468-3083.2011.04066.x.

241. Vadoud-Seyedi J, Simonart T. Treatment of axillary hyperhidrosis with botulinum toxin type A reconstituted in lidocaine or in normal saline: a randomized, side-by-side, double-blind study. Br J Dermatol. 2007;156(5):986–989. doi: 10.1111/j.1365-2133.2007.07760.x.

242. Hayton MJ, Stanley JK, Lowe NJ. A review of peripheral nerve blockade as local anaesthesia in the treatment of palmar hyperhidrosis. Br J Dermatol. 2003;149(3):447–451. doi: 10.1046/j.1365-2133.2003.05593.x.

243. Solomon P. Modified Bier block anesthetic technique is safe for office use for botulinum a toxin treatment of palmar and plantar hyperhidrosis. Dermatol Online J. 2007;13:6. doi: 10.5070/D36g96v8fb.

244. Ponce-Olivera RM, Tirado-Sánchez A, Arellano-Mendoza MI, León-Dorantes G, Kassian-Rank S. Palmar hyperhidrosis. Safety efficacy of two anaesthetic techniques for botulinum toxin therapy. Dermatol Online J. 2006;12:9. doi: 10.5070/D39gn4x65f.

245. De Almeida ART, Kadunc BV, De Oliveira EMM. Improving botulinum toxin therapy for palmar hyperhidrosis: wrist block and technical considerations. Dermatol Surg. 2001;27:34–36. doi: 10.1097/00042728-200101000-00010.

246. Fujita M, Mann T, Mann O, Berg D. Surgical pearl: use of nerve blocks for botulinum toxin treatment of palmar-plantar hyperhidrosis. J Am Acad Dermatol. 2001;45(4):587–589. doi: 10.1067/mjd.2001.116341.

247. Grunfeld A, Murray CA, Solish N. Botulinum toxin for hyperhidrosis: a review. Am J Clin Dermatol. 2009;10(2):87–102. doi: 10.2165/00128071-200910020-00002.

248. Lowe NJ, Glaser DA, Eadie N, et al. Botulinum toxin type A in the treatment of primary axillary hyperhidrosis: a 52-week multicenter double-blind, randomized, placebo-controlled study of efficacy and safety. J Am Acad Dermatol. 2007;56(4):604–611. doi: 10.1016/j.jaad.2007.01.009.

249. Naumann M, Lowe NJ, Kumar CR, Hamm H Hyperhidrosis Clinical Investigators Group. Botulinum toxin type A is a safe and effective treatment for axillary hyperhidrosis over 16 months: a prospective study. Arch Dermatol. 2003;139(6):731–736. doi: 10.1001/archderm.139.6.731.

250. Schnider P, Moraru E, Kittler H, et al. Treatment of focal hyperhidrosis with botulinum toxin type A: long-term follow-up in 61 patients. Br J Dermatol. 2001;145(2):289–293. doi: 10.1046/j.1365-2133.2001.04349.x.

251. Cameron AE. Selecting the right patient for surgical treatment of hyperhidrosis. Thorac Surg Clin. 2016;26(4):403–406. doi: 10.1016/j.thorsurg.2016.06.004.

252. Breach NM. Axillary hyperhidrosis: surgical cure with aesthetic scars. Ann R Coll Surg Engl. 1979;61:295–297.